Abstract
This Practice Point commentary discusses the findings and limitations of a phase III trial by Spinowitz et al. that compared oral and intravenous iron therapies in nondialysis patients with chronic kidney disease. In total, 304 patients were randomly assigned in a 3:1 ratio to receive either two 510mg doses of intravenous ferumoxytol within 5±3 days or 200mg of elemental oral iron daily for 21 days. At day 35, hemoglobin levels had increased significantly more in patients who had received intravenous ferumoxytol than in those who had received oral iron therapy. Ferumoxytol was well tolerated. The superiority of ferumoxytol over other intravenous iron preparations, however, needs to be investigated, and optimal serum ferritin levels for the nondialysis CKD population need to be defined.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hörl WH (2007) Clinical aspects of iron use in the anemia of kidney disease. J Am Soc Nephrol 18: 382–393
Deicher R and Hörl WH (2006) New insights into the regulation of iron homeostasis. Eur J Clin Invest 36: 301–309
Spinowitz BS et al. (2008) Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol 19: 1599–1605
Van Wyck DB et al. (2006) A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int 68: 2846–2856
Agarwal R et al. (2006) A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol 26: 445–454
Stoves J et al. (2001) A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrol Dial Transplant 16: 967–974
Charytan C et al. (2005) Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract 100: c55–c62
Macdougall IC et al. (2005) Administration of intravenous iron sucrose as a 2-minute push to CKD patients: a prospective evaluation of 2,297 injections. Am J Kidney Dis 46: 283–289
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author has declared associations with the following companies: Pharmacosmos Pharmaceuticals (honoraria) and Vifor-International (consultant).
Rights and permissions
About this article
Cite this article
Hörl, W. Comparing the efficacy of intravenous iron and oral iron in nondialysis patients with chronic kidney disease. Nat Rev Nephrol 4, 530–531 (2008). https://doi.org/10.1038/ncpneph0913
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpneph0913